Fumaderm efficacy and quality of life study

[Fred]

Yes Jim it's a study, but you may like this one. It was published in The British Journal of Dermatology

This observational study recorded data on quality of life, treatment efficacy and drug dosing in patients suffering from psoriasis treated with Fumaderm® under conditions of daily practice in 78 dermatological centres.

Quote:

---

Patients and methods:
In this prospective, multicenter, non-interventional trial we included adult patients with severe plaque psoriasis under outpatient conditions receiving Fumaderm® according to the current summary of product characteristics for systemic treatment of psoriasis. At baseline and after 3, 6 and 12 months the dosing regimen under daily conditions, dermatology life quality index (DLQI), and clinical efficacy with the psoriasis area and severity index (PASI) were documented.

Results:
A total of 249 patients were included. The mean DLQI score at study entry was 9.95, the mean PASI was 16.8. The average treatment dose of Fumaderm® was 2.8 tablets daily. More than 70% of patients were treated with 1 to 3 tablets daily and <30% were treated with a dose ranging from 4 to 6 tablets daily. DLQI and PASI improved in the entire study population by 67.2% and 66.6%, respectively. Specifically, when analyzing patients who started Fumaderm® within 4 weeks before baseline the mean DLQI score decreased from 11.8 to 2.9 (75% reduction) and the mean PASI score from 19.84 to 7.35 after 12 months (63% improvement).

Conclusion:
This is the first field study analyzing the use of Fumaderm® and the improvement of quality of life in patients with psoriasis under daily outpatient conditions. The improvement of DLQI obtained with Fumaderm® was comparable to the improvement observed in patients with psoriasis treated with modern biologics. Importantly, in most patients with good clinical response the treatment dose was 1 to 3 tablets daily.

Source:

[To see links please register here]